DPD Testing Before Treatment With Fluoropyrimidines in the Amsterdam UMCs: An Evaluation of Current Pharmacogenetic Practice

DPD Testing Before Treatment With Fluoropyrimidines in the Amsterdam UMCs: An Evaluation of Current Pharmacogenetic Practice

IntroductionThe fluoropyrimidines (FP) (5-Fluorouracil, capecitabine, and tegafur) are commonly used anti-cancer drugs, but lead to moderate to severe toxicity in about 10–40% of patients. DPD testing [either the enzyme activity of dihydropyrimidine dehydrogenase (DPD) or the DPYD genotype] identifi...

Full description

Bibliographic Details
Main Authors: Forike K. Martens, Daan W. Huntjens, Tessel Rigter, Meike Bartels, Pierre M. Bet, Martina C. Cornel
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-01-01
Series:Frontiers in Pharmacology
Subjects:
DPYD gene polymorphism
fluoropyridine
pharmacogenomics and personalised medicine
toxicicity
electronic patient record
qualitative & quantitative analyses
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2019.01609/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2019.01609/full

Similar Items